血源性外泌体ncRNA对结直肠癌诊断价值的Meta分析*

倩倩; 王举; 杨斯帅; 刘继伟; 彭际奎

doi:10.16833/j.cnki.jbmc.2025.11.009

包头医学院学报 >

2025 , Vol. 41 >Issue 11: 48 - 54

DOI: https://doi.org/10.16833/j.cnki.jbmc.2025.11.009

临床医学论著

血源性外泌体ncRNA对结直肠癌诊断价值的Meta分析^*

倩倩 ,
王举 ,
杨斯帅 ,
刘继伟 ,
彭际奎

展开

1.内蒙古科技大学包头医学院研究生学院,内蒙古包头 014040;
2.内蒙古自治区人民医院胃肠外科

收稿日期: 2025-03-05

网络出版日期: 2025-12-17

基金资助

*内蒙古医科大学科技百万工程联合项目(项目编号:YKD2020KJBW(LH)068);内蒙古自治区人民医院院内基金项目(项目编号:2019YN22)

收起

Meta-analysis of the diagnostic value of blood-derived exosomal ncRNA for colorectal cancer

QIAN Qian ,
WANG Ju ,
YANG Sishuai ,
LIU Jiwei ,
PENG Jikui

Expand

1. Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou 014040, China;
2. Department of Gastrointestinal Surgery, Inner Mongolia Autonomous Region People′s Hospital

Received date: 2025-03-05

Online published: 2025-12-17

Fold

摘要

目的: 通过Meta分析评价血源性外泌体携带非编码RNA对结直肠癌的诊断价值,为结直肠癌的精准诊疗提供临床依据。方法: 应用计算机检索PubMed、Embase、Web of Science等数据库,检索建库以来至2024年4月10日期间公开发表的有关外泌体诊断结直肠癌的文献。根据纳入和排除标准进行文献筛选和资料提取,采用QUADAS-2量表对纳入文献进行质量评估。使用stata、Review Manager和Meta-DiSc软件分析纳入的文献数据,汇总单项研究的敏感性(sensitivity, SEN)、特异性(specificity, SPE)、阳性似然比(positive likelihood ratio, PLR)、阴性似然比(negative likelihood ratio, NLR)、诊断优势比(diagnostic odds ratio, DOR)、受试者曲线(receiver operating characteristic, ROC)和曲线下面积(area under the curve, AUC)等指标,通过亚组分析、敏感性分析和绘制二元箱线图探究异质性来源,制作漏斗图测定发表偏倚。结果: 共纳入12篇文献,包含17种外泌体非编码RNA。Meta分析结果显示,SEN、SPE、PLR、NLR、DOR和AUC分别是0.84(95%CI:0.80-0.88)、0.77(95%CI:0.71-0.82)、3.64(95%CI:2.97-4.45)、0.21(95%CI:0.17-0.26)、17.60(95%CI:13.17-23.52)、和0.88(95%CI:0.84-0.90)。亚组分析后发现外泌体LncRNA的敏感性0.92(95%CI:0.75-0.98)和AUC值0.92(95%CI:0.89-0.94),均高于其他组。结论: 外泌体携带非编码RNA具有更高的SEN和SPE,有望成为检测结直肠癌精准的诊断工具。

关键词： 结直肠癌; 外泌体; 生物标记物; Meta分析

本文引用格式

倩倩 , 王举 , 杨斯帅 , 刘继伟 , 彭际奎 . 血源性外泌体ncRNA对结直肠癌诊断价值的Meta分析^*[J]. 包头医学院学报, 2025 , 41(11) : 48 -54 . DOI: 10.16833/j.cnki.jbmc.2025.11.009

Abstract

Objective: To evaluate the diagnostic value of blood-derived exosomes carrying non-coding RNA in colorectal cancer by Meta-analysis, and to provide clinical basis for accurate diagnosis and treatment of colorectal cancer. Methods: Computer-based searches were conducted in databases including PubMed, Embase, and Web of Science to retrieve publicly published literatures on exosomes for colorectal cancer diagnosis from the establishment of each database up to April 10, 2024. Literature screening and data extraction were performed in accordance with the inclusion and exclusion criteria, and the quality of the included literatures was assessed using the QUADAS-2 scale. Software including Stata, Review Manager, and Meta-DiSc was used to analyze the data of the included literatures, and indicators of individual studies were summarized, such as sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), receiver operating characteristic (ROC) curve, and area under the curve (AUC). Subgroup analysis, sensitivity analysis, and the drawing of bivariate box plots were conducted to explore the sources of heterogeneity, and funnel plots were generated to detect publication bias. Results: A total of 12 literatures were included, covering 17 types of exosomal non-coding RNAs. The results of the Meta-analysis showed that the SEN, SPE, PLR, NLR, DOR, and AUC were 0.84 (95%CI: 0.80-0.88), 0.77 (95%CI: 0.71-0.82), 3.64 (95%CI: 2.97-4.45), 0.21 (95%CI:0.17-0.26), 17.60 (95%CI: 13.17-23.52), and 0.88 (95%CI: 0.84-0.90), respectively. After subgroup analysis, it was found that the sensitivity of exosomal LncRNA was 0.92 (95%CI: 0.75-0.98) and its AUC value was 0.92 (95%CI: 0.89-0.94), both of which were higher than those of other subgroups. Conclusion: Exosomes carrying non-coding RNAs have relatively high SEN and SPE, and are expected to become an accurate diagnostic tool for the detection of colorectal cancer.

Key words： Colorectal cancer; Exosomes; Biomarkers; Meta-analysis

参考文献

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Bresalier RS. Colorectal cancer screening in a changing world[J]. Gastroenterol Clin North Am, 2022, 51(3): 577-591.
[3] Oliveira JW, Moraes RA, Mehanna SH, et al. Colorectal cancer: histopathological profile and prevalence of DNA repair system deficiency in patients submitted to surgical treatment in a university hospital[J]. Braz Arch Dig Surg, 2023, 36: e1771.
[4] Zhao R, Xia DG, Chen YW, et al. Improved diagnosis of colorectal cancer using combined biomarkers including Fusobacterium nucleatum, fecal occult blood, transferrin, CEA, CA19-9, gender, and age[J]. Cancer Med, 2023, 12(13): 14636-14645.
[5] Zhang Y, Bi JY, Huang JY, et al. Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications[J]. Int J Nanomedicine, 2020, 15: 6917-6934.
[6] Qi Y, Xu RJ, Song CX, et al. A comprehensive database of exosome molecular biomarkers and disease-gene associations[J]. Sci Data, 2024, 11(1): 210.
[7] Xu B B, Zhu YD, Cao CC, et al. Recent advances in RNA structurome[J]. Sci China Life Sci, 2022, 65(7): 1285-1324.
[8] Pegtel DM, Gould SJ. Exosomes[J]. Annu Rev Biochem, 2019, 88: 487-514.
[9] Dou QY, Wang JZ, Yang YS, et al. Roles of exosome-derived non-coding RNA in tumor micro-environment and its clinical application[J]. J Zhejiang Univ Med Sci, 2023, 52(4): 429-438.
[10] Umwali Y, Yue CB, Gabriel ANA, et al. Roles of exosomes in diagnosis and treatment of colorectal cancer[J]. World J Clin Cases, 2021, 9(18): 4467-4479.
[11] Yang KK, Zhou QB, Qiao BB, et al. Exosome-derived noncoding RNAs: function, mechanism, and application in tumor angiogenesis[J]. Mol Ther Nucleic Acids, 2022, 27: 983-997.
[12] Kilchert C. RNA exosomes and their cofactors[J]. Methods Mol Biol, 2020, 2062: 215-235.
[13] Zou SL, Chen YL, Ge ZZ, et al. Downregulation of serum exosomal miR-150-5p is associated with poor prognosis in patients with colorectal cancer[J]. Cancer Biomark, 2019, 26(1): 69-77.
[14] Zhao YH, Du TT, Du LT, et al. Long noncoding RNA LINC02418 regulates MELK expression by acting as a CeRNA and may serve as a diagnostic marker for colorectal cancer[J]. Cell Death Dis, 2019, 10(8): 568.
[15] Shi YT, Zhuang YY, Zhang JL, et al. Four circulating exosomal miRNAs as novel potential biomarkers for the early diagnosis of human colorectal cancer[J]. Tissue Cell, 2021, 70: 101499.
[16] Li TK, Zhou TT, Wu J, et al. Plasma exosome-derived circGAPVD1 as a potential diagnostic marker for colorectal cancer[J]. Transl Oncol, 2023, 31: 101652.
[17] Xie Y, Li J, Li PL, et al. RNA-seq profiling of serum exosomal circular RNAs reveals circ-PNN as a potential biomarker for human colorectal cancer[J]. Front Oncol, 2020, 10: 982.
[18] Pan B, Qin J, Liu XX, et al. Identification of serum exosomal hsa-circ-0004771 as a novel diagnostic biomarker of colorectal cancer[J]. Front Genet, 2019, 10: 1096.
[19] Barbagallo C, Brex D, Caponnetto A, et al. LncRNA UCA1, upregulated in CRC biopsies and downregulated in serum exosomes, controls mRNA expression by RNA-RNA interactions[J]. Mol Ther Nucleic Acids, 2018, 12: 229-241.
[20] Liu XX, Pan B, Sun L, et al. Circulating exosomal miR-27a and miR-130a act as novel diagnostic and prognostic biomarkers of colorectal cancer[J]. Cancer Epidemiol Biomarkers Prev, 2018, 27(7): 746-754.
[21] Graham LD, Pedersen SK, Brown GS, et al. Colorectal neoplasia differentially expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas[J]. Genes Cancer, 2011, 2(8): 829-840.
[22] Zhang N, Zhang PP, Huang JJ, et al. Reduced serum exosomal miR-874 expression predicts poor prognosis in colorectal cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(2): 664-672.
[23] Wang L, Song XG, Yu M, et al. Serum exosomal miR-377-3p and miR-381-3p as diagnostic biomarkers in colorectal cancer[J]. Future Oncol, 2022, 18(7): 793-805.
[24] Li N, Li J, Mi Q, et al. Long non-coding RNA ADAMTS9-AS1 suppresses colorectal cancer by inhibiting the Wnt/β-catenin signalling pathway and is a potential diagnostic biomarker[J]. J Cell Mol Med, 2020, 24(19): 11318-11329.
[25] Zhang Y, Wang Y, Zhang BQ, et al. Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer[J]. Biomed Pharmacother, 2023, 163: 114786.
[26] Tang QS, Yang S, He GP, et al. Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy[J]. Cancer Lett, 2022, 548: 215823.
[27] Xu ZJ, Chen Y, Ma L, et al. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment[J]. Mol Ther, 2022, 30(10): 3133-3154.
[28] Wang J, Yan FH, Zhao Q, et al. Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer[J]. Sci Rep, 2017, 7(1): 4150.
[29] Maminezhad H, Ghanadian S, Pakravan K, et al. A panel of six-circulating miRNA signature in serum and its potential diagnostic value in colorectal cancer[J]. Life Sci, 2020, 258: 118226.
[30] Xie ZJ, Xia J, Jiao MX, et al. Exosomal lncRNA HOTAIR induces PDL1⁺ B cells to impede anti-tumor immunity in colorectal cancer[J]. Biochem Biophys Res Commun, 2023, 644: 112-121.
[31] Oehme F, Krahl S, Gyorffy B, et al. Low level of exosomal long non-coding RNA HOTTIP is a prognostic biomarker in colorectal cancer[J]. RNA Biol, 2019, 16(10): 1339-1345.
[32] Zhang F, Jiang JJ, Qian H, et al. Exosomal circRNA: emerging insights into cancer progression and clinical application potential[J]. J Hematol Oncol, 2023, 16(1): 67.
[33] He JH, Xi NT, Han ZP, et al. The role of liquid biopsy analytes in diagnosis, treatment and prognosis of colorectal cancer[J]. Front Endocrinol, 2022, 13: 875442.
[34] Yu D, Li YX, Wang MY, et al. Exosomes as a new frontier of cancer liquid biopsy[J]. Mol Cancer, 2022, 21(1): 56.
[35] Tamkovich SN, Yunusova NV, Somov AK, et al. Comparative sub-population analysis of exosomes from blood plasma of cancer patients[J]. Biomed Khim, 2018, 64(1): 110-114.
[36] Yin H, Hu JJ, Ye ZY, et al. Serum long non-coding RNA NNT-AS1 protected by exosome is a potential biomarker and functions as an oncogene via the miR-496/RAP2C axis in colorectal cancer[J]. Mol Med Rep, 2021, 24(2): 585.
[37] Mahmoudi T, Pourhassan-Moghaddam M, Shirdel B, et al. On-site detection of carcinoembryonic antigen in human serum[J]. Biosensors, 2021, 11(10): 392.
[38] Zheng R, Zhang K, Tan SY, et al. Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3-eIF3h interaction[J]. Mol Cancer, 2022, 21(1): 49.
[39] Pathania AS, Prathipati P, Challagundla KB. New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2): 188624.
[40] Gu CZ, Shang AQ, Liu GG, et al. Identification of CD147-positive extracellular vesicles as novel non-invasive biomarkers for the diagnosis and prognosis of colorectal cancer[J]. Clin Chim Acta, 2023, 548: 117510.
[41] Tang YT, Huang YY, Zheng L, et al. Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum[J]. Int J Mol Med, 2017, 40(3): 834-844.
[42] Yang DB, Zhang WH, Zhang HY, et al. Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics[J]. Theranostics, 2020, 10(8): 3684-3707.
[43] Ludwig N, Whiteside TL, Reichert TE. Challenges in exosome isolation and analysis in health and disease[J]. Int J Mol Sci, 2019, 20(19): 4684.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献